Flecainide

Co-administration contraindicated due to potential for cardiac arrhythmias.

Class I antiarrhythmic. Amiodarone inhibits flecainide metabolism. Reserve concomitant use; initiate at lower dose and reduce previous dose by 30-50%.

Flecainide inhibits cytochrome P450 2D6, potentially causing toxic amitriptyline levels; may require lower amitriptyline doses.

CYP2D6 substrate with narrow therapeutic index. Dose adjustment likely required due to cinacalcet's strong CYP2D6 inhibition.

Cinacalcet is a strong CYP2D6 inhibitor. Dose adjustments may be required, particularly for drugs with narrow therapeutic index such as flecainide.

Type 1C antiarrhythmic that inhibits P450 2D6 and may increase clomipramine plasma levels, potentially causing toxicity.

Type IC antiarrhythmic that inhibits P450 2D6; may increase desipramine concentrations and toxicity risk; dose adjustment may be needed.

Type 1C antiarrhythmic that inhibits cytochrome P450 2D6, increasing imipramine plasma concentration. May require dose adjustment and TCA plasma level monitoring.

Type 1C antiarrhythmic that inhibits P450 2D6, potentially increasing nortriptyline plasma concentrations to toxic levels.

Flecainide inhibits cytochrome P450 2D6, potentially causing toxic amitriptyline concentrations; dose reduction may be necessary.

Flecainide inhibits P450 2D6, potentially causing abrupt toxicity in patients stable on trimipramine due to increased plasma concentrations.

Flecainide (Type 1C antiarrhythmic) inhibits cytochrome P450 2D6, which may increase amoxapine plasma concentrations and require dose adjustment.

CYP2D6 substrate; bupropion inhibits CYP2D6 and increases flecainide concentrations; consider dose reduction.

Bupropion inhibits CYP2D6 and can increase flecainide concentrations; consider dose reduction of flecainide.

CYP2D6 substrate Type 1C antiarrhythmic. Bupropion inhibits CYP2D6, increasing flecainide exposure. Dose reduction may be necessary.

CYP2D6 substrate Type 1C antiarrhythmic. Bupropion inhibits CYP2D6 and can increase flecainide concentrations. Consider dose reduction of flecainide when used with bupropion.

CYP2D6-metabolized Type 1C antiarrhythmic. Bupropion inhibits CYP2D6 and can increase flecainide concentrations. Consider dose reduction.

Darifenacin may increase flecainide exposure as it is metabolized by CYP2D6 with narrow therapeutic window. Caution should be taken when used concomitantly.

Caution when used concomitantly; darifenacin may increase exposure of flecainide, a CYP2D6 substrate with narrow therapeutic window.

Type 1C antiarrhythmic that inhibits cytochrome P450 2D6, which may increase doxepin plasma concentrations. Concomitant use may require lower doses and monitoring.

Type 1C antiarrhythmic that inhibits P450 2D6, increasing imipramine plasma concentrations. May require dose adjustment and TCA level monitoring.

Bupropion inhibits CYP2D6 and can increase flecainide concentrations. Consider dose reduction when using with CONTRAVE.

Amiodarone inhibits metabolism of flecainide; reduce dose and monitor carefully.

Insufficient experience with concomitant use with nifedipine; concurrent use not recommended.

Paroxetine inhibits CYP2D6, increasing flecainide exposure. Decrease flecainide dosage if needed with concomitant paroxetine use.

Paroxetine inhibits CYP2D6, increasing exposure of flecainide. Dosage reduction may be needed.

Flecainide is predominantly metabolized by CYP450 2D6. Coadministration requires careful monitoring and may require dose reduction.

Terbinafine inhibits CYP450 2D6, the primary metabolic pathway for flecainide. Careful monitoring and dose reduction may be required.

Flecainide is predominantly metabolized by CYP450 2D6; terbinafine inhibition may increase exposure. Careful monitoring and dose reduction may be required.

Flecainide inhibits cytochrome P450 2D6, increasing trimipramine maleate plasma concentrations and risk of toxicity.

Potential for drug-drug interaction due to possible competition for active tubular secretion via base-secreting system.